Keros Therapeutics, Inc. (KROS) Stock

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc. is led by CEO Jasbir S. Seehra, employs 163 people, headquartered in US, publicly traded since 2020.

Keros Therapeutics, Inc. (KROS) stock trades at $11.28 with a market capitalization of $223.65M. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.07, reflecting a net loss over the last twelve months, price-to-book of 0.86, price-to-sales of 15.00. Over the past 52 weeks the stock has ranged between $9.69 and $22.55, and currently trades 50.0% below its 52-week high.

On profitability, Keros Therapeutics, Inc. generates a return on equity (ROE) of -21.40% (negative, reflecting a net loss), return on capital employed of -36.84%, an operating margin of 29.10%, a net profit margin of -553.88%.

Keros Therapeutics, Inc. by the numbers, 2018–2025

Between 2018 and 2025 Keros Therapeutics, Inc. reported revenue of $10.0M rising to $244.0M, a change of +2340.0% across 8 years. Compounded, revenue has grown —% a year over five years, —% over three, 6000.0% over the last twelve months. Net profit rose to $87.0M.

Operating margin went from -16.9% in 2018 to 28.9% in 2025, a gain of 45.9 percentage points. The most recent net margin is -553.88%. On a trailing twelve-month basis to Jun '26, revenue is $14.0M and net profit $-83.0M.

Borrowings rose from $1.0M to $17.0M, cash from operations was $108.0M in the latest year, positive in 2 of the last 8.

Return on equity has averaged -22.4% over five years, and was 28.7% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Keros Therapeutics, Inc. (KROS) — frequently asked questions